Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Stier H, Vos E, Kenley D
Journal of Endocrinology and Metabolism (2013) · n=925
Integrated safety across six randomised, double-blind, placebo-controlled AOD-9604 trials (~925 subjects, doses to 54 mg oral, durations to 24 weeks): no IGF-1 elevation, no insulin resistance, no impaired glucose tolerance, no anti-AOD-9604 antibodies, and no serious adverse events attributed to study drug. The published file that compounding-pharmacy AOD-9604 marketing in 2026 most commonly cites.
This is the integrated safety summary published in the Journal of Endocrinology and Metabolism in 2013 by Heike Stier (analytica International, Loerrach, Germany), Evert Vos, and David Kenley — a secondary review consolidating safety and tolerability data across the six randomised, double-blind, placebo-controlled clinical trials Metabolic Pharmaceuticals Ltd ran on AOD-9604 between 2001 and 2007. The paper is the closest thing to a peer-reviewed publication of the Phase I and Phase II AOD-9604 human dataset and is the source the 2026 marketing literature for the molecule most commonly cites when claiming an FDA-grade safety record.
The integrated dataset summarised here covered approximately 925 adult subjects across the six trials, with single-dose intravenous and subcutaneous Phase I work running up to 54 mg, multiple-dose Phase IIa and Phase IIb oral protocols running up to 24 weeks, and a single-dose IV cardiovascular-safety study. The headline safety findings are consistently null on the parameters most relevant to a growth-hormone-derived candidate: AOD-9604 did not raise serum IGF-1 at any tested dose, did not impair carbohydrate metabolism on oral glucose tolerance testing in contrast with full-length hGH, did not induce detectable anti-AOD-9604 antibody formation in the immunogenicity panels run across the program, and did not produce an excess of treatment-related serious adverse events versus the placebo arms across the integrated dataset. Reported treatment-emergent adverse events were dominated by mild gastrointestinal and headache events at frequencies that did not differentiate statistically from placebo. The authors conclude that AOD-9604 displays "a very good safety and tolerability profile indistinguishable from placebo" — the framing that subsequently underpinned the originator company's 2014 Generally Recognized As Safe self-determination for the molecule as a food and supplement ingredient.
The structural fact this paper documents and does not resolve is that the same dataset showing AOD-9604 is clinically inert on the off-target hGH-axis parameters also showed that AOD-9604 is clinically inert on its intended weight-loss endpoint. The 2007 Phase IIb (METAOD006) failure that ended the obesity development program is acknowledged but the efficacy results were never separately published in a peer-reviewed journal; the integrated efficacy story is reported alongside the safety story here. The /peptides/aod-9604 page treats this paper as the central reconcilable evidence between the rodent-positive preclinical case (Ng 2000, Heffernan 2001) and the negative pivotal-trial outcome that the /critic/aod-9604-fat-loss-claims response addresses in detail.
This is a Tier 2 integrated safety review authored by parties commercially adjacent to the AOD-9604 program (the corresponding author affiliation and Metabolic Pharmaceuticals connection are disclosed in the paper itself), published in a journal that does not carry the impact-factor weight of Lancet-register safety publications, and not subject to the kind of regulatory-grade integrated summary of safety review that FDA New Drug Application files trigger. The reviewed dataset is a clean-safety dataset for a compound that also failed its primary efficacy endpoint, which constrains what the safety profile can mean: the absence of detectable on- and off-target pharmacological signal at the human doses tested is consistent both with a clean compound and with a compound that does not engage its target receptor effectively at the dose ranges studied. Long-term exposure beyond 24 weeks, parenteral subcutaneous chronic dosing (the route the contemporary compounding-pharmacy use of the molecule actually employs), and exposure in populations beyond the relatively healthy obese adults the trials enrolled are all outside the dataset this paper integrates. The Phase IIa results presented as the NAASO 2005 conference abstract (Herd et al. 2005) and the Phase IIb (METAOD006) results that ended the program were not separately published as peer-reviewed efficacy primary papers; this safety summary is what the published record offers in their place, and it should not be cited as substantively a Phase IIb efficacy publication, which it is not.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.